NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free ADIL Stock Alerts $1.79 +0.03 (+1.70%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.76▼$1.9250-Day Range$0.83▼$3.2652-Week Range$0.77▼$14.00Volume243,343 shsAverage Volume4.78 million shsMarket Capitalization$7.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Adial Pharmaceuticals alerts: Email Address Ad StockEarningsThe AI Stock that’s Disrupting Every IndustryMove over Nvidia. There’s a new hot AI play that has soared 960% in the past year. One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia…Here's the Ticker >>> About Adial Pharmaceuticals Stock (NASDAQ:ADIL)Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Read More ADIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADIL Stock News HeadlinesApril 26, 2024 | americanbankingnews.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short InterestApril 24, 2024 | uk.investing.comAdial Pharmaceuticals secures new addiction treatment patentMay 3, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 22, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeApril 22, 2024 | benzinga.comEXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US PatentApril 22, 2024 | globenewswire.comAdial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeApril 11, 2024 | msn.comWhy Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars TodayApril 11, 2024 | msn.comDow Falls Over 1%; US Inflation Rate Accelerates In MarchMay 3, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 10, 2024 | marketwatch.comAdial Pharmaceuticals Shares Rise 78% After Positive Trial Data for AD04April 10, 2024 | msn.comAdial stock rallies 81% on data for alcohol abuse drugApril 10, 2024 | investorplace.comWhy Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?April 10, 2024 | msn.comEXCLUSIVE: Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety, Patient ComplianceApril 10, 2024 | finance.yahoo.comAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderApril 10, 2024 | globenewswire.comAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderApril 2, 2024 | globenewswire.comAdial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateMarch 19, 2024 | investing.comAdial Pharmaceuticals Inc (ADIL)March 16, 2024 | finance.yahoo.comMASI Apr 2024 120.000 callMarch 16, 2024 | finance.yahoo.comMASI Apr 2024 125.000 putMarch 11, 2024 | benzinga.comPeering Into Adial Pharmaceuticals's Recent Short InterestMarch 1, 2024 | globenewswire.comAdial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsMarch 1, 2024 | investing.comAdial Pharmaceuticals secures new patent for AD04 drugFebruary 28, 2024 | msn.comWhy Adial Pharmaceuticals Stock Is Blasting OffFebruary 28, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeFebruary 28, 2024 | finance.yahoo.comEXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use DisorderFebruary 28, 2024 | globenewswire.comAdial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeFebruary 15, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc.: Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20See More Headlines Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today5/02/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-250.52% Return on Assets-183.24% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.73Miscellaneous Outstanding Shares4,050,000Free Float3,468,000Market Cap$7.25 million OptionableNo Data Beta1.40 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Cary John Claiborne MBA (Age 63)CEO, President & Director Comp: $728.31kDr. Bankole A. Johnson DSc (Age 64)FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer Comp: $435kMr. Joseph A. M. Truluck M.B.A. (Age 46)MBA, CFO, Treasurer & Secretary Comp: $358.49kMr. Tony Goodman (Age 60)COO & Director Comp: $33kMr. John R. Martin J.D.Chief Legal OfficerMs. Catherine FratilaControllerMore ExecutivesKey CompetitorsTFF PharmaceuticalsNASDAQ:TFFPEnveric BiosciencesNASDAQ:ENVBShuttle PharmaceuticalsNASDAQ:SHPHPulmatrixNASDAQ:PULMCadrenal TherapeuticsNASDAQ:CVKDView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 159,000 shares on 2/13/2024Ownership: 9.578%Kevin SchuylerBought 700 shares on 9/29/2023Total: $1,918.00 ($2.74/share)View All Insider TransactionsView All Institutional Transactions ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed in 2024? Adial Pharmaceuticals' stock was trading at $1.86 at the beginning of the year. Since then, ADIL stock has decreased by 3.8% and is now trading at $1.79. View the best growth stocks for 2024 here. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 1,010,000 shares, an increase of 11,509.2% from the March 31st total of 8,700 shares. Based on an average trading volume of 6,220,000 shares, the short-interest ratio is currently 0.2 days. Currently, 26.7% of the company's stock are sold short. View Adial Pharmaceuticals' Short Interest. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its quarterly earnings results on Wednesday, August, 11th. The company reported ($6.25) EPS for the quarter, missing analysts' consensus estimates of ($5.00) by $1.25. When did Adial Pharmaceuticals' stock split? Adial Pharmaceuticals's stock reverse split before market open on Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager. Who are Adial Pharmaceuticals' major shareholders? Adial Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James W Jr Newman, Kevin Schuyler and William B Stilley III. View institutional ownership trends. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADIL) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
